• Barron's Take

    Subscriber ContentRead Preview

    Pharmasset a Key Asset for Gilead

    Gilead shares are tumbling after the company offered an 89% premium to buy Pharmasset and its promising hepatitis C drugs for $11 billion. We, however, see ample upside for Gilead investors.

  • The Striking Price Daily | Steven M. Sears

    Subscriber ContentRead Preview

    Feasting on a Likely Chinese Takeout

    Use call options to bet that for-profit online university ChinaCast Education will be acquired at a premium price.

  • key = SUBSCRIBER CONTENT LOG IN or SUBSCRIBE»

    All subscriber content available for preview.

  • PENTA:
    Advice for the Wealthy

    Pitcairn Goes Global

    By Richard C. Morais
    Pitcairn, a multi-family office in Pa., is tapping an international consortium of family offices in its hunt to uncover best practices and investment ideas across the globe.

Columns

  • Streetwise
    [Santoli_BC]

    Puzzling Over a Market's Thrusts

    By MICHAEL SANTOLI

    Bulls, bears ponder a range of outcomes. Plus, E* Trade's future.

  • ETF Focus
    [BA_Coleman_0927]

    Bunker Strategy:
    Japanese Banks

    By MURRAY COLEMAN

    Although Japan's growth is sluggish, the world's No. 3 economy is doing better than the West. In particular, large financial institutions are worth a look. The most liquid ETF with big-bank exposure has a 17% stake in the sector. Investors might want to top up with the stock of some individual names.

Real-Time Analysis

PENTA:
Advice for the Wealthy

  • Pitcairn Goes Global

    By Richard C. Morais
    Pitcairn, a multi-family office in Pa., is tapping an international consortium of family offices in its hunt to uncover best practices and investment ideas across the globe.

Welcome to Barron’s

Editor and President Ed Finn explains how you can use Barron's to become a better investor. Watch video

 

Highlights